LetterLetter
Febuxostat Desensitization in a Patient with Previous Stevens-Johnson Syndrome and HLA-B*58:01 Genotype
TENNEILLE TANA and PETER VADAS
The Journal of Rheumatology September 2019, 46 (9) 1250-1251; DOI: https://doi.org/10.3899/jrheum.181051
TENNEILLE TANA
Division of Allergy and Clinical Immunology, St. Michael’s Hospital, Toronto, Ontario, Canada.
MD, MScPETER VADAS
Division of Allergy and Clinical Immunology, St. Michael’s Hospital, Toronto, Ontario, Canada.
MD, PhDREFERENCES
- 1.↵
- 2.↵
- Yu K,
- Yu C,
- Fang Y
- 3.↵
- Khanna D,
- Fitzgerald J,
- Khanna P,
- Bae S,
- Singh M,
- Neogi T,
- et al;
- American College of Rheumatology
- 4.↵
- Jutkowitz E,
- Dubreuil M,
- Lu N,
- Kuntz K,
- Choi H
- 5.↵
- US Food and Drug Administration
- 6.↵
- Lien YH,
- Logan JL
- 7.↵
- Yu K,
- Lai J,
- Hsu P,
- Chen D,
- Chen C,
- Lin H
- 8.↵
- Chohan S
- 9.↵
- Sulaiman N,
- Othman A,
- Shahril N,
- Rashid A,
- Noh M
- 10.↵
- Di Paolo C,
- Minetti S,
- Mineni M,
- Inverardi S,
- Rizzini FL,
- Cinquini M,
- et al.
In this issue
The Journal of Rheumatology
Vol. 46, Issue 9
1 Sep 2019
Febuxostat Desensitization in a Patient with Previous Stevens-Johnson Syndrome and HLA-B*58:01 Genotype
TENNEILLE TANA, PETER VADAS
The Journal of Rheumatology Sep 2019, 46 (9) 1250-1251; DOI: 10.3899/jrheum.181051